Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 19;13(4):1362.
doi: 10.3390/nu13041362.

Precision Nutrition for Alzheimer's Prevention in ApoE4 Carriers

Affiliations
Review

Precision Nutrition for Alzheimer's Prevention in ApoE4 Carriers

Nicholas G Norwitz et al. Nutrients. .

Abstract

The ApoE4 allele is the most well-studied genetic risk factor for Alzheimer's disease, a condition that is increasing in prevalence and remains without a cure. Precision nutrition targeting metabolic pathways altered by ApoE4 provides a tool for the potential prevention of disease. However, no long-term human studies have been conducted to determine effective nutritional protocols for the prevention of Alzheimer's disease in ApoE4 carriers. This may be because relatively little is yet known about the precise mechanisms by which the genetic variant confers an increased risk of dementia. Fortunately, recent research is beginning to shine a spotlight on these mechanisms. These new data open up the opportunity for speculation as to how carriers might ameliorate risk through lifestyle and nutrition. Herein, we review recent discoveries about how ApoE4 differentially impacts microglia and inflammatory pathways, astrocytes and lipid metabolism, pericytes and blood-brain barrier integrity, and insulin resistance and glucose metabolism. We use these data as a basis to speculate a precision nutrition approach for ApoE4 carriers, including a low-glycemic index diet with a ketogenic option, specific Mediterranean-style food choices, and a panel of seven nutritional supplements. Where possible, we integrate basic scientific mechanisms with human observational studies to create a more complete and convincing rationale for this precision nutrition approach. Until recent research discoveries can be translated into long-term human studies, a mechanism-informed practical clinical approach may be useful for clinicians and patients with ApoE4 to adopt a lifestyle and nutrition plan geared towards Alzheimer's risk reduction.

Keywords: Alzheimer’s disease; ApoE4; astrocytes; blood–brain barrier; inflammation; insulin resistance; microglia; precision nutrition.

PubMed Disclaimer

Conflict of interest statement

N.G.N. and R.S.I. have published books for lay audiences on dietary advice for the prevention of Alzheimer’s disease or optimization of metabolic health from which they stand to gain royalties. Author N.G.N. declares all royalties go to advancing research and providing education to patients and the lay public. R.S.I. has also served as a consultant for Avanair, Genentech/Roche and Biogen.

Figures

Figure 1
Figure 1
Precision nutrition for ApoE4 carriers. ApoE4 can contribute to NLRP3-mediated disease-associated microglia (DAM) formation, disease-associated astrocyte (DAA) formation, activation of the CypA-NFκB-MMP9 pathway in pericytes and loss of blood–brain barrier (BBB) integrity, and insulin resistance. The text described specific nutritional recommendations to target these pathways, including the following options: low-carbohydrate (LC) or ketogenic diets that generate βhB; extra virgin olive oil containing oleocanthal (OC) and hydroxytyrosol (HXT); cruciferous vegetables containing sulphoraphane (SFN); fatty fish containing DHA and DHA supplementation; Quercetin (Q) supplementation, also found in capers and red onions; resveratrol (R) supplementation; vitamins D3 and K2MK7 (DK) supplementation; vitamin B-complex (B); and low-dose lithium (Li) supplementation.

References

    1. Cummings J.L., Morstorf T., Zhong K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res. Ther. 2014;6:37. doi: 10.1186/alzrt269. - DOI - PMC - PubMed
    1. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80:1778–1783. doi: 10.1212/WNL.0b013e31828726f5. - DOI - PMC - PubMed
    1. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Jr., Kaye J., Montine T.J., et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–292. doi: 10.1016/j.jalz.2011.03.003. - DOI - PMC - PubMed
    1. Alzheimer’s Association Is Alzheimer’s Genetic? [(accessed on 3 March 2021)]; Available online: https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-ri....
    1. Michaelson D.M. APOE epsilon4: The most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement. 2014;10:861–868. doi: 10.1016/j.jalz.2014.06.015. - DOI - PubMed

Substances

LinkOut - more resources